These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31734445)

  • 41. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.
    Zeven K; De Groof TWM; Ceuppens H; Awad RM; Ertveldt T; de Mey W; Meeus F; Raes G; Breckpot K; Devoogdt N
    Front Immunol; 2023; 14():1268900. PubMed ID: 37799715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
    Adams GP; Schier R; McCall AM; Crawford RS; Wolf EJ; Weiner LM; Marks JD
    Br J Cancer; 1998 May; 77(9):1405-12. PubMed ID: 9652755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.
    Steffen AC; Orlova A; Wikman M; Nilsson FY; Ståhl S; Adams GP; Tolmachev V; Carlsson J
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):631-8. PubMed ID: 16538504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
    Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of [
    Bala G; Baudhuin H; Remory I; Gillis K; Debie P; Krasniqi A; Lahoutte T; Raes G; Devoogdt N; Cosyns B; Hernot S
    Mol Imaging Biol; 2018 Apr; 20(2):260-267. PubMed ID: 28875290
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
    Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
    Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer.
    Lwin TM; Hernot S; Hollandsworth H; Amirfakhri S; Filemoni F; Debie P; Hoffman RM; Bouvet M
    Surgery; 2020 Jul; 168(1):85-91. PubMed ID: 32370916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
    Tolmachev V; Mume E; Sjöberg S; Frejd FY; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Apr; 36(4):692-701. PubMed ID: 19066886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. (99m)Tc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice.
    Ma W; Kang F; Wang Z; Yang W; Li G; Ma X; Li G; Chen K; Zhang Y; Wang J
    Amino Acids; 2013 May; 44(5):1337-45. PubMed ID: 23456486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.
    Li R; Attari A; Prytyskach M; Garlin MA; Weissleder R; Miller MA
    Cytometry A; 2020 May; 97(5):528-539. PubMed ID: 31423731
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
    Hauck ML; Zalutsky MR
    Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Linear Desferrichrome-Linked Silicon-Rhodamine Antibody Conjugate Enables Targeted Multimodal Imaging of HER2 in Vitro and in Vivo.
    Ahn SH; Thach D; Vaughn BA; Alford VM; Preston AN; Laughlin ST; Boros E
    Mol Pharm; 2019 Mar; 16(3):1412-1420. PubMed ID: 30714739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies.
    Bannas P; Well L; Lenz A; Rissiek B; Haag F; Schmid J; Hochgräfe K; Trepel M; Adam G; Ittrich H; Koch-Nolte F
    Contrast Media Mol Imaging; 2014; 9(2):135-42. PubMed ID: 24523058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
    Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
    J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
    J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.